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Abstract 
Objectives 
To assess the impact of a history of liver metastases on survival in patients undergoing surgery for 
lung metastases from colorectal carcinoma. 
Methods 
We reviewed recent studies identified by searching MEDLINE and EMBASE using the Ovid 
interface, with the following search terms: lung metastasectomy, pulmonary metastasectomy, lung 
metastases and lung metastasis, supplemented by manual searching. Inclusion criteria were that the 
research concerned patients with lung metastases from colorectal cancer undergoing surgery with 
curative intent, and had been published between 2007 and 2014. Exclusion criteria were that the paper 
was a review, concerned surgical techniques themselves (without follow-up), and included patients 
treated non-surgically. Using Stata 14, we performed aggregate data and individual data meta-
analysis using random-effect and Cox multilevel models respectively. 
Results 
We collected data on 3501 patients from 17 studies. The overall median survival was 43 months. In 
aggregate data meta-analysis, the hazard ratio for patients with previous liver metastases was 1.19 
(95% CI 0.90–1.47), with low heterogeneity (I2 4.3%). In individual data meta-analysis, the hazard 
ratio for these patients was 1.37 (95% CI 1.14–1.64; p < 0.001). Multivariate analysis identified the 
following factors significantly affecting survival: tumour-infiltrated pulmonary lymph nodes (p < 
0.001), type of resection (p = 0.005), margins (p < 0.001), carcinoembryonic antigen levels (p < 
0.001), and number and size of lung metastases (both p < 0.001). 
Conclusions 
A history of liver metastases is a negative prognostic factor for survival in patients with lung 
metastases from colorectal cancer. We registered the meta-analysis protocol in PROSPERO 
(CRD42015017838). 
 
 
 
Introduction 
Pulmonary metastasectomy has become the standard treatment for patients with lung metastases from 
colorectal cancer (CRC) [1]. In Western countries, colon canceris the most prevalent type of cancer 
considering both sexes [2], and 50% of patients with this type of cancer will 
develop metastases during the course of the disease, primarily in the liver, lung or both [2]. 
Although a large number of studies have been published with data on survival after surgical resection 
of lung metastases [3], there are certain outstanding issues, including a lack of agreement on the 
best prognostic factors. In 1997, to address this issue, the International Registry of Lung Metastases 
reported the prognostic factors associated with this type of surgery, after analysing survival rates in a 
sample of more than 5000 patients [4]. A decade later, in 2007, Pfannschmidt and colleagues 
conducted a systematic review to identify specific prognostic factors in patients with lung metastases 
from CRC [3]. Since then, many different factors have been found to be associated with prolonged 
survival after lung metastasectomy in patients with CRC [5], [6], [7]: prolonged disease-free interval, 
low pre-thoracotomy carcinoembryonic antigen (CEA) levels, a single lung metastasis less than 3 cm 
in diameter and the absence of thoracic lymph node involvement. However, the real impact of a 
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history of resected liver metastases on survival outcomes following lung metastasectomy remains 
uncertain [5]. 
In 2013, Gonzalez et al. [8] published a systematic review and meta-analysis of papers published 
between 2000 and 2011. They analysed seven studies that took into account previous liver metastasis 
and concluded that a history of resected liver metastasis is not correlated with a higher risk of 
mortality in these patients (hazard ratio, HR 1.22, 95% CI: 0.91–1.64; p = 0.022); however, the 
observed high heterogeneity of the data analysed might have influenced the interpretation and the 
conclusions in that analysis. Given the uncertainties about the impact of a history of resected liver 
metastasis on survival outcomes of CRC following lung metastasectomy, we sought to conduct a 
systematic review of recent scientific literature, considering papers published since Pfannschmidt's 
2007 systematic review [3], and asking authors for their collaboration to enable us to perform an 
individual data meta-analysis. The aim of this study was to provide the best evidence on a question 
of great current interest, namely, the impact of a history of liver metastases on survival of patients 
undergoing surgery for lung metastases from CRC. 
 
Materials and methods 
Search strategy 
Studies were identified by searching MEDLINE and EMBASE using the Ovid interface, 
supplemented by a manual search of the reference lists of the papers retrieved. The following terms 
were used: lung metastasectomy, pulmonary metastasectomy, lung metastases and lung metastasis. 
All the search terms were combined using the Boolean operator “OR” to increase the likelihood 
of retrieving all relevant articles, and the search was limited to publications between 2007 and 2014. 
Fig. 1 is a diagram showing the flow of papers through the study. We sought to identify papers that 
analysed variables with an impact on survival after lung metastasectomy in patients with colorectal 
cancer. To identify papers that met all the inclusion criteria and none of the exclusion criteria, two 
reviewers independently assessed the relevance of the papers identified, by reading the titles, then the 
abstracts and, finally, by reading the full paper and confirming that they had some data relevant to 
our research question; disagreements were resolved by discussion and consensus. The inclusion 
criteria were that the research was in consecutive patients with lung metastases from colorectal cancer 
undergoing surgery with curative intent, and had been published between 2007 and 2014, considering 
both retrospective and prospective studies. When a study led to more than one paper, we used data 
from the most recent publication. The exclusion criteria considered were that the paper was a review, 
concerned the surgical techniques themselves, did not report follow-up of patients undergoing 
surgery, or included patients treated with non-surgical approaches (stereotactic radiotherapy or 
radiofrequency ablation). This process resulted in the selection of a total of 29 papers. 
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Fig. 1. Flow chart of the search and selection process. 
 
 
 
 
Data collection 
We registered the protocol for the meta-analysis with PROSPERO (registration number 
CRD42015017838; supplementary file 1) and drafted a collaboration agreement to share specific data 
(Supplementary file 2). Additionally, we designed a database to store all the data we wanted to analyse 
from the studies of interest and the study was approved by the clinical research ethics committee of 
the Gipuzkoa health region. To contact study authors, we initially sent an email explaining our interest 
to the corresponding author cited on the paper retrieved. If we did not receive a reply, we sent emails 
directly to the other authors and we also attempted to contact some authors via social media, including 
Facebook, Twitter and ResearchGate.  
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Statistical analysis 
We performed two types of meta-analysis. First, we carried out conventional meta-analysis of 
aggregate data with both crude and adjusted estimates using a random-effect model. Second, we 
carried out one-step meta-analysis of individual participant data using a multilevel Cox model with 
the patients as level 1 units and the studies as level 2 units. We fitted both a univariate model with 
the main variable (previous liver metastasectomy) and a multivariate model. The variables in these 
models (as for the meta-analysis of aggregate data) were selected a priori with clinical criteria, seeking 
to control for confounding factors, with no modelling strategy. To be able to include random effects 
on the intercept and slope of the model (to allow for heterogeneity between studies in baseline risk 
and effect respectively), the Cox model was simulated using a Poisson model [9]. As a measure of 
heterogeneity, we used the median hazard ratio (MHR), that can be interpreted as the median relative 
change in the hazard of the occurrence of the outcome when comparing identical subjects from two 
randomly selected studies ordered by risk [10]. The assumption of proportional risk for the main 
variable given the other variables was tested by introducing a term for interaction with time. 
 
Results 
Studies included 
We selected 29 papers that met all the selection criteria and divided them into two broad groups: 6 
which did not analyse the variable of interest [2], [6], [7], [11], [12], [13], that is, whether patients 
who underwent surgery had a history of resected liver metastases; and the other 23 which did consider 
this variable [1], [5], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], 
[29], [30], [31], [32], [33]. In this second group of 23 papers, there were 21 patient series, 1 
prospective [15] and the others retrospective [5], [14], [16], [17], [18], [19], [20], [21], [22], [23], 
[24], [25], [26], [27], [28], [29], [30], [31], [32], and 2 meta-analyses [1], [8] (these including several 
of the selected patient series). In total, we collected data from 17 studies [2], [5], [12], [13], [14], [16], 
[17], [18], [20], [21], [25], [26], [27], [28], [30], [32], [33], managing to obtain data on 3501 patients 
for the meta-analysis of individual data. The authors from three studies [6], [15], [31] replied to the 
first email, expressing interest in the study, but did not communicate further, and did not provide any 
information or explain their reasons; one author replied declining to participate in the study [19]; and 
authors of the other studies [7], [11], [22], [23], [24], [29] did not respond to any of our attempts to 
contact them. 
Descriptive analysis 
The mean age of patients who underwent surgery was 62.7 years (range: 19–94), 2126 (60.7%) were 
male, and 744 (20%) had a history of liver metastases. Table 1summarises the main descriptive 
variables of the study, as well as their distribution as a function of whether patients had previously 
had liver metastasis. 
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Table 1. Main descriptive variables of the study (univariate analysis). 
Study variable Number of 
patients with this 
type of data 
All cases No previous liver 
metastasis 
Previous liver 
metastasis 
p 
Age in years, mean (SD) 3500 62.7 (10.33) 63.17 (10.12) 60.81 (10.89) 0.061 
Sex: male, n (%) 3501 2126 (60.7) 1662 (60.3) 464 (62.4) 0.302 
Disease-free interval in 
months, mean (SD) 
3331 34.01 (35.12) 34.33 (36.8) 32.83 (28.27) 0.351 
Number of lung metastasis, 
mean (SD) 
2821 1.97 (2.09) 1.87 (1.93) 2.33 (2.56) <0.001 
Size of metastases, mean 
(SD) 
2876 2.35 (1.54) 2.44 (1.50) 2.06 (1.36) 0.002 
Lymph node involvement: 
positive, n (%) 
2095 401 (19.1) 328 (19.5) 73 (17.5) 0.343 
Surgery: video-assisted 
thoracic, n (%) 
2459 608 (17.4) 485 (24.4) 123 (26.2) 0.440 
Preoperative CEA: positive, 
n (%) 
3025 1035 (34.2) 831 (34.8) 204 (32.0) 0.190 
Margins: positive, n (%) 2953 156 (5.3) 92 (4) 64 (10) <0.001 
Origin: rectal, n (%) 2534 1212 (47.8) 1015 (50.2) 197 (38.5) <0.001 
CEA: carcinoembryonic antigen; SD: standard deviation. 
 
 
 
Survival analysis 
The overall median survival from lung metastasectomy was 64 months (range: 0–275 months), while 
the 3- and 5-year survival rates were 68.6% and 51.9% respectively. In the univariate analysis, we 
did not find significant differences by sex (p = 0.261) or site of the primary tumour (colon or rectum) 
(p = 0.254). The type of surgery performed was close to significance (p = 0.055). We did find 
statistically significant differences for the following variables: lymph node involvement 
(p < 0.001), CEAlevel (p < 0.001), state of the surgical margins (p < 0.001), history of liver 
metastases (p < 0.001), disease-free interval (p = 0.029), number of metastases (p < 0.001) and their 
size (p < 0.001). Fig. 2 shows the Kaplan-Meier survival curves as a function of whether patients had 
previously had liver metastases. 
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Fig. 2. Kaplan–Meier survival curves for the 3501 patients included in the study. 
 
 
 
Previous liver metastasis 
For the group of 744 patients with a history of liver metastases, we estimated a median survival of 
51.8 months (95% CI: 46.11–57.49), with mean 3- and 5-year survival rates of 64% and 44.5%, 
respectively. In patients for whom there were data on the time elapsed between the appearance of 
liver and lung metastasis, we found that 135 (49.5%) patients had metachronous metastases and 138 
(50.5%) synchronous metastases. We did not find significant differences in survival between these 
groups, with mean survival of 55 (95% CI 41.5–68.4) and 46 (95% CI: 37.61–54.39) months among 
those with synchronous and metachronous metastases, respectively (p = 0.215). 
Aggregate data and individual participant data meta-analysis 
Two types of aggregate data meta-analysis were performed with raw and adjusted data 
(Fig. 3, Fig. 4). Fig. 3 shows the aggregate data meta-analysis, with all the participating studies. We 
excluded the studies of Landes [21] and Nojiri [33] from the analysis, because they only included 
patients with a history of liver metastases, and hence could not be used to study the impact of previous 
liver metastasis on survival. 
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Fig. 3. Forest plot for the aggregate data meta-analysis of the raw data. 
 
 
 
 
Fig. 4. Forest plot for the adjusted aggregate data meta-analysis. 
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In both the adjusted aggregate data meta-analysis and the individual participant data meta-analysis, 
to assess the impact of previous liver metastasis, we adjusted for variables which from a clinical point 
of view are associated with prognosis, namely, sex, age, mediastinal lymph node involvement, type 
of resection, surgical margin status, number of metastases and their size, preoperative CEA levels, 
and disease-free interval (for this analysis we included 1779 patients, where all this variables were 
recorded). 
The combined estimator (for previous liver metastasis) obtained from aggregate data using a random-
effect model did not reach statistical significance (HR = 1.19, 95% CI 0.90–1.47), with a low level 
of heterogeneity (I2 4.3%) (see also Fig. 4, a Forest plot for the adjusted aggregate data meta-analysis 
with the studies that included all the variables to perform the adjustment). In contrast, the estimator 
obtained from the individual participant data meta-analysis, using an adjusted multilevel random 
effects Cox model (Table 2), was statistically significant (HR = 1.37, 95% CI 1.14–1.64). Though no 
heterogeneity was detected in effects, there was heterogeneity in baseline risks (MHR = 1.17, 95% 
CI 1.07–1.47). 
 
 
 
Table 2. Individual data meta-analysis (multilevel random effects). 
Variable Hazard ratio 95% CI Std error Z p 
Previous liver metastasis 1.37 1.14–1.64 0.13 3.44 0.001 
Sex 0.92 0.79–1.08 0.07 −0.99 0.323 
Age 1.00 0.99–1.01 0.01 0.99 0.324 
Positive lymph nodes 1.83 1.44–2.32 0.22 4.96 <0.001 
Positive margins 1.81 1.35–2.42 0.27 3.95 <0.001 
Size of metastases 1.12 1.06–1.18 0.03 4.10 <0.001 
Preoperative CEA level 1.51 1.28–1.77 0.13 4.86 <0.001 
Disease-free interval 0.99 0.99–0.99 0.001 −2.05 0.040 
Number of metastases 1.07 1.04–1.09 0.10 6.86 <0.001 
Lobectomy (vs wedge) 0.78 0.63–0.96 0.08 −2.31 0.021 
Pneumonectomy (vs wedge) 2.34 0.56–9.73 1.70 1.17 0.243 
CEA: carcinoembryonic antigen. 
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Discussion 
What factors are prognostic of lung metastases is a topic of ongoing debate, and this is reflected in 
the numerous studies analysing potentially relevant factors [1], [3], [4], [8]. In 1997, the International 
Registry of Lung Metastases published its results, finding only disease-free survival, the radicality of 
the surgery, and the number of lymph nodes removed to be determinant [4], but since then, several 
studies have indicated a wider range of prognostic factors, such as mediastinal lymph 
nodeinvolvement, preoperative CEA levels or age [5], [6], [7]. 
To date, however, no results have been published from clinical trials on lung metastasectomy. We 
await the results of the PulMICC trial for good quality scientific evidence to clarify uncertainties 
related to this type of surgery [34], but meanwhile, systematic reviews of case series are the best 
source of scientific evidence. In 2007, Pfannschmidt et al. researched lung metastases from colorectal 
cancer in detail, conducting a systematic review and a meta-analysis to assess prognostic factors, and 
found that up to that point, little attention had been paid to whether patients had a history of liver 
metastases [3]. Later Gonzalez [8] carried out a new systematic review and meta-analysis including 
four studies that had been published after 2007. Three out of these four studies found that a history 
of resected liver metastases was associated with shorter survival [5], [21], [22]. 
In our new systematic review, we have found 21 papers published since 2007 that assessed survival 
after resection of lung metastases from colorectal cancer taking into account patients' history of liver 
metastases. Like Gonzalez [8], we found a great heterogeneity in the studies, with some authors 
reporting their results as mean survival time [5], [16], [17], [18] (with or without confidence 
intervals), 5-year survival rates [20], [27], or HRs [30], while others simply stated that differences 
were not statistically significant, without reporting the actual results [28], [30]. Gonzalez 
et al. [8] reviewed papers published between 2000 and 2011. They analysed seven studies that took 
into account previous liver metastasis and concluded that a history of resected liver metastases is not 
correlated with a higher risk of mortality in these patients (HR 1.22, 95% CI: 0.91–1.64), but also 
highlighted the high heterogeneity of the data analysed (p = 0.022). Seeking to improve on that 
analysis, we decided to conduct a meta-analysis of individual data, to assess the impact of a history 
of liver metastases on survival, and we have found that patients who have previously undergone liver 
metastasectomy have poorer survival (HR 1.37, 95% CI: 1.14–1.64). 
To our knowledge, this is the first time that an individual data meta-analysis has been performed to 
analyse survival after lung metastases, and for this, we have assembled the series with the largest 
number of patients with metastasis with a colorectal origin published to date. In the meta-analysis 
published by Gonzalez [8], four negative prognostic factors were identified: short disease-free 
interval (HR 1.59; 95% CI 1.27–1.98), the presence of lymph node involvement (HR 1.65; 95% CI 
1.35–2.02), having more than one lung metastasis (HR 2.04; 95% CI 1.72–2.41) and high CEA levels 
(HR 1.91; 95% CI 1.57–2.32). The results obtained from analysing the large sample of patients we 
have assembled enable us to add the following to this list of negative prognostic factors: positive 
surgical margins (HR 1.81; 95% CI 1.35–2.43), larger metastases (HR 1.12; 95% CI 1.06–1.18) and 
a history of liver metastases (HR 1.37; 95% CI 1.15–1.64). The statistical analysis performed, 
simulating the Cox model with a Poisson model, has allowed us to study the heterogeneity not only 
in baseline risk but also in effects. Specifically, this modelling was necessary to enable us to rule out 
heterogeneity in the effects and it allows us to conclude that, despite the baseline risk of patients 
varying between studies included, the effect on survival of the factors analysed, in particular, that of 
a history of previous liver metastases, is similar across the studies. 
One fact that has caught our attention is the amount of missing data: in 1406 cases there was no data 
on lymph node involvement, in 1001 cases it was not known if the primary tumour was rectal or 
colon, in 1042 cases we did not know the surgical approach chosen and there was a lack of data on 
the size or number of metastases in 600 patients. We believe that the absence of data supports the 
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need to make the extra effort involved in obtaining individual data to perform individual data meta-
analysis of individual data, as this will achieve the most reliable results. 
We should also point out that we found shorter survival in patients who underwent surgery 
with wedge resection rather than lobectomy (HR 0.78, 95% CI: 0.63–0.96). Hernández 
et al. [35] made a similar observation based on analysing the results of a Spanish prospective 
multicentre study, and a few years earlier, Lin et al. [22] also observed a shorter survival in patients 
who underwent less complete resection. These results do not allow us to recommend lobectomies in 
patients undergoing pulmonary metastasectomy, but do suggest a new avenue for research. 
Specifically, it would be interesting to carry out a prospective randomised study comparing the two 
techniques, deciding a priori which type of lymphadenectomy is to be performed [35]. 
 
Conclusions 
Given the results of our meta-analysis of individual participant data, it can be concluded that a history 
of liver metastases prior to resection of lung metastasesfrom colorectal carcinoma is associated with 
a poorer prognosis. In addition, other factors have been found to have an impact on survival after 
lung metastasectomy, namely, disease-free interval, lymph node involvement, infiltrated surgical 
margins, preoperative CEA levels, the number of resected lung metastases and their size. 
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